287 related articles for article (PubMed ID: 3998474)
1. Complement-mediated serum cytotoxicity for Leishmania major amastigotes: killing by serum deficient in early components of the membrane attack complex.
Hoover DL; Berger M; Hammer CH; Meltzer MS
J Immunol; 1985 Jul; 135(1):570-4. PubMed ID: 3998474
[TBL] [Abstract][Full Text] [Related]
2. Killing of Leishmania tropica amastigotes by factors in normal human serum.
Hoover DL; Berger M; Nacy CA; Hockmeyer WT; Meltzer MS
J Immunol; 1984 Feb; 132(2):893-7. PubMed ID: 6690622
[TBL] [Abstract][Full Text] [Related]
3. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of lethal effect of human serum upon Leishmania donovani.
Pearson RD; Steigbigel RT
J Immunol; 1980 Nov; 125(5):2195-201. PubMed ID: 7430624
[TBL] [Abstract][Full Text] [Related]
5. Human peritoneal macrophages. Production in vitro of the active terminal complement components C5 to C9 and a functional alternative pathway of complement. Brief report.
Hetland G; Bungum L
APMIS; 1988 Jan; 96(1):89-92. PubMed ID: 3345254
[TBL] [Abstract][Full Text] [Related]
6. The release of C5a in complement-activated serum does not require C6.
Biesecker G; Wagner JL; Hugli TE
J Immunol; 1989 Aug; 143(4):1228-32. PubMed ID: 2545783
[TBL] [Abstract][Full Text] [Related]
7. Activation of the alternative complement pathway by Leishmania promastigotes: parasite lysis and attachment to macrophages.
Mosser DM; Edelson PJ
J Immunol; 1984 Mar; 132(3):1501-5. PubMed ID: 6363545
[TBL] [Abstract][Full Text] [Related]
8. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
Densen P; McRill CM; Ross SC
J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
[TBL] [Abstract][Full Text] [Related]
9. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
Hammer CH; Hänsch G; Gresham HD; Shin ML
J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
[TBL] [Abstract][Full Text] [Related]
10. Terminal complement components play a role in the expression of C5a.
Gresham HD; Renfer L; Hammer CH; Frank MM
J Immunol; 1987 Feb; 138(3):838-41. PubMed ID: 3805718
[TBL] [Abstract][Full Text] [Related]
11. Complement-mediated killing of the Lyme disease spirochete Borrelia burgdorferi. Role of antibody in formation of an effective membrane attack complex.
Kochi SK; Johnson RC; Dalmasso AP
J Immunol; 1991 Jun; 146(11):3964-70. PubMed ID: 2033266
[TBL] [Abstract][Full Text] [Related]
12. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
[TBL] [Abstract][Full Text] [Related]
13. Hereditary C5 deficiency in man. III. Studies of hemostasis and platelet responses to zymosan.
Breckenridge RT; Rosenfeld SI; Graff KS; Leddy JP
J Immunol; 1977 Jan; 118(1):12-6. PubMed ID: 830743
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
15. The interaction of Escherichia coli with normal human serum: the kinetics of serum-mediated lipopolysaccharide release and its dissociation from bacterial killing.
Tesh VL; Duncan RL; Morrison DC
J Immunol; 1986 Aug; 137(4):1329-35. PubMed ID: 3525676
[TBL] [Abstract][Full Text] [Related]
16. Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-9.
Puentes SM; Da Silva RP; Sacks DL; Hammer CH; Joiner KA
J Immunol; 1990 Dec; 145(12):4311-6. PubMed ID: 2147941
[TBL] [Abstract][Full Text] [Related]
17. Evidence that C5b recognizes and mediates C8 incorporation into the cytolytic complex of complement.
Stewart JL; Kolb WP; Sodetz JM
J Immunol; 1987 Sep; 139(6):1960-4. PubMed ID: 3624872
[TBL] [Abstract][Full Text] [Related]
18. Inherited deficiencies of the late-acting complement components other than C9 found among healthy blood donors.
Inai S; Akagaki Y; Moriyama T; Fukumori Y; Yoshimura K; Ohnoki S; Yamaguchi H
Int Arch Allergy Appl Immunol; 1989; 90(3):274-9. PubMed ID: 2592116
[TBL] [Abstract][Full Text] [Related]
19. Complement-induced ultrastructural membrane lesions: requirement for terminal components.
Packman CH; Rosenfeld SI; Weed RI; Leddy JP
J Immunol; 1976 Nov; 117(5 Pt.2):1883-9. PubMed ID: 993584
[TBL] [Abstract][Full Text] [Related]
20. The C5b-9 complex: subunit composition of the classical and alternative pathway-generated complex.
Podack ER; Kolb WP; Muller-Eberhard HJ
J Immunol; 1976 May; 116(5):1431-4. PubMed ID: 1270802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
